A significant number of TNBC tumor samples showing intense NIS staining8, can now be modulated further by HDACi, and thus eventually may improve the scope of applying NIS-based targeted radioiodide therapy for this subgroup of patients. The gene discussed is SLC5A5; the disease is neoplasm.